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A B S T R A C T
Objective: To evaluate the diagnostic performance of TB-LAMP, a manual molecular tuberculosis (TB)
detection method, and provide comparison to the Xpert MTB/RIF assay.
Methods: In a large multicentre study, two sputum samples were collected from participants with TB
symptoms in reference laboratories in Peru, South Africa, Brazil, and Vietnam. Each sample was tested
with TB-LAMP. The reference standard consisted of four direct smears, four cultures, and clinical and
radiological ﬁndings. Individuals negative on conventional tests were followed up after 8 weeks. The
Xpert MTB/RIF assay was performed on fresh or frozen samples as a molecular test comparison.
Results: A total of 1036 adults with suspected TB were enrolled. Among 375 culture-conﬁrmed TB cases
with 750 sputum samples, TB-LAMP detected 75.6% (95% conﬁdence interval (CI) 71.8–79.4%), including
97.9% (95% CI 96.4–99.4%) of smear-positive TB samples and 46.6% (95% CI 40.6–52.7%) of smear-negative
TB samples. Speciﬁcity in 477 culture-negative participants not treated for TB (954 sputum samples) was
98.7% (95% CI 97.9–99.6%). TB-LAMP test results were indeterminate in 0.3% of cases.
Conclusions: TB-LAMP detects nearly all smear-positive and half of smear-negative TB cases and has a
high speciﬁcity when performed in reference laboratories. Performance was similar to the Xpert MTB/RIF
assay.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
In 2016, an estimated 10.4 million people worldwide developed
tuberculosis (TB) and 1.3 million HIV-negative people died from
the disease (World Health Organization, 2017). The lack of rapid
and accurate diagnostic tools contributed to the estimated 4.1
million cases of TB that went unreported (TDR, FIND SA, 2006).
Smear microscopy, the ﬁrst line in TB detection, has a low and
variable sensitivity (30–70%) (Steingart et al., 2006; Aber et al.,
1980; Urbanczik, 1985). Conventional culture on solid media has a
sensitivity of 80–90%, but requires 2–8 weeks for a result (Lee et al.,
2003; Somoskövi et al., 2000). Although conventional liquid
culture (Mycobacteria Growth Indicator Tube (MGIT); Becton
Dickinson Microbiology Systems) typically has sensitivity greater
than 95%, the time to result is still up to 4 weeks. This results in
individuals being lost to follow-up and treatment delays (Stall
et al., 2011).
The use of molecular methods such as nucleic acid ampliﬁca-
tion tests (NAAT) may promise faster results with high sensitivity
and speciﬁcity. The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA,
USA) is an automated molecular method based on PCR. Initial
demonstration studies found the sensitivity to be 77% in those with
smear-negative, culture-positive TB and speciﬁcity to be >98%
(Boehme et al., 2010; Boehme et al., 2011). A Cochrane review in
2014 found sensitivity in those with smear-negative, culture-
positive TB to be 67% and speciﬁcity to be 99% (Steingart et al.,
2014). However, Xpert MTB/RIF requires a continuous supply of
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electricity, hefty investment in equipment, and long-term main-
tenance plans.
TB-LAMP is a new, commercially available, manual molecular
TB detection method based on the novel loop-mediated isothermal
ampliﬁcation platform (LAMP), manufactured by Eiken Chemical
Co. in Japan. LAMP is an attractive diagnostics platform because it
takes less than 2 h to perform, requires minimal instrumentation,
and generates a ﬂuorescent result that can be detected with the
naked eye (Notomi et al., 2000). Furthermore, it has shown
potential as a cross-disease platform, with assays developed for
malaria, African trypanosomiasis, severe acute respiratory syn-
drome, and inﬂuenza (Kuboki et al., 2003; Poon et al., 2005a,b,
2006). The TB-LAMP assay requires only minimal instrumentation
in the form of a heating block. Additionally, it has the potential for
higher throughput as it can test up to 14 samples per test run
(Boehme et al., 2011; Vassall et al., 2011). A full description of the
TB-LAMP procedure can be found in the recent World Health
Organization (WHO) policy guidance (WHO Policy Guidance,
2016).
This study aimed to determine the accuracy of TB-LAMP in a
single raw sputum sample in comparison to conventional methods
and the Xpert MTB/RIF assay when performed in quality-assured
TB reference laboratories.
Study population and methods
TB reference laboratories were selected in four urban centres:
Cape Town in South Africa, Lima in Peru, Ho Chi Minh City in
Vietnam, and Rio de Janeiro in Brazil. The reference laboratories
selected were enrolled in national or international quality
assurance programmes and had each undergone a laboratory
assessment by FIND prior to selection. The study was approved by
the institutional review boards in all countries. Informed consent
was obtained from all participants. Additionally, while participants
may have received better than standard diagnostic care through
the use of additional cultures, clinicians were blinded to the results
of TB-LAMP so as not to impact patient care.
Adults (18 years) with symptoms suggestive of pulmonary TB,
as deﬁned by national TB programmes, were enrolled consecu-
tively if they were able to provide two sputum samples of at least
1.5 ml and had not received TB treatment in the preceding 60 days.
Each of the two sputum samples obtained had 60 ml removed
for TB-LAMP and approximately 10 ml for direct Ziehl–Neelsen
(ZN) and/or light-emitting diode (LED) ﬂuorescence microscopy
(FM) smear (Figure 1). The TB-LAMP technician was blinded to the
smear results and vice versa. The remaining sputum was then
processed with n-acetyl-L-cysteine–sodium hydroxide
(NALCNaOH) and used for solid culture (Löwenstein–Jensen
medium) and MGIT liquid culture (WHO, 1998; Siddiqi and
Ruesch-Gerdes, 2006). The ﬁrst positive culture from the two
performed per sample (two samples per individual) underwent
conﬁrmation of Mycobacterium tuberculosis (MTB) complex by
MPT64 antigen detection (Capilia TB; Tauns Laboratories) (Hill-
emann et al., 2005).
A scanty positive culture was deﬁned as a positive MGIT at
>28 days from inoculation or a Löwenstein–Jensen with <20
colonies. A culture-positive TB case was diagnosed if a participant
had either two scanty or any non-scanty positive MTB culture
result, consistent with previous analysis of molecular TB diag-
nostics (Boehme et al., 2010, 2011). Non-tuberculous mycobacteria
(NTM) or mixed cases were analyzed separately.
Samples from culture-positive TB cases were further classiﬁed
as smear-positive or smear-negative based on a single smear test
performed on that sputum. A smear-positive TB sample required
one or more acid-fast bacilli per 100 ﬁelds for ZN or per 400 ﬁelds
for FM (scanty grade or higher) following WHO recommendations
(World Health Organization, 2007). A smear-negative TB sample
had no acid-fast bacilli detected by ZN or FM whatsoever, but was
found through culture testing to be a culture-positive TB case.
Samples from participants with all cultures negative and any
positive smear were analyzed separately.
Any participant with all smear results negative and all four
cultures negative (or up to two cultures contaminated and the
remaining negative), was considered bacteriologically negative for
TB. Bacteriologically negative participants found to be TB-LAMP-
positive on either sputum specimen were sought for clinical and
laboratory follow-up after 8 weeks. Bacteriologically negative
participants found to be TB-LAMP-negative were also followed up
wherever programmatically possible.
A non-TB case was deﬁned as a participant who was
bacteriologically negative and for whom no TB treatment was
prescribed (based on adjunct diagnostics such as chest X-ray and/
or symptoms) at enrolment or during follow-up after 8 weeks.
Bacteriologically negative participants who were treated empiri-
cally at enrolment or follow-up were considered to have clinically
diagnosed TB. Such decisions were at the discretion of each
physician and were subject to local variation.
Those initially bacteriologically negative with any positive
culture at follow-up were reclassiﬁed as culture-positive TB. Those
with no laboratory conﬁrmation but either unimproved chest X-
ray (i.e., physician compared a follow-up chest X-ray to the initial
chest X-ray and found it to be ‘same abnormal’ or ‘worse’) or non-
remitting symptoms (i.e., physician described symptoms as ‘same’
or ‘worse’) at follow-up were reclassiﬁed as possible TB and
analyzed separately.
If the TB-LAMP technician could not determine from the
ﬂuorescent read-out whether TB-LAMP was positive or negative, a
second reader was asked to make the determination. If the second
read was also indeterminate, a second TB-LAMP test was repeated
on the same sputum sample wherever possible. Each run of up to
14 TB-LAMP tests at one time included a negative and a positive
control. If the negative control is positive, this indicates potential
DNA contamination and all tests in that run must be repeated after
decontamination procedures. If the positive control is negative,
Figure 1. Sample ﬂow (Abbreviations: ZN, Ziehl–Neelsen microscopy; FM, ﬂuorescence microscopy; NALCNaOH, n-acetyl-L-cysteine–sodium hydroxide; PBS, phosphate-
buffered saline; Xpert, Xpert MTB/RIF; User A, the technician performing TB-LAMP and blinded to the smear results; User B, the technician performing smears and blinded to
the TB-LAMP results).
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this indicates probable reagent degradation and all tests in that run
must be repeated with new reagents. The overall indeterminate
rate indicates the lack of a clear result and the need for a repetition
of the test from any of these causes.
The performance of TB-LAMP on a single raw sputum sample
was evaluated against the reference standard of two direct ZN
smears, two direct FM smears, and four cultures per patient.
Because a TB-LAMP test was performed on each of the two samples
submitted per participant, correlations in the results were
accounted for by using bootstrapping with sampling by cluster,
where each set of two samples was the cluster, to obtain exact
standard errors to calculate correct 95% conﬁdence intervals (95%
CI) for a single raw sample.
The performance of the Xpert MTB/RIF assay was evaluated as a
molecular test comparison to TB-LAMP. In Peru and South Africa,
where the assay was already available and in use, the Xpert MTB/
RIF assay was performed on freshly concentrated sputum, whereas
in Brazil and Vietnam, the Xpert assay was performed on sputum
that had been frozen for 2–6 months. The Xpert MTB/RIF assay was
performed after NALCNaOH concentration from the ﬁrst sputum
sample collected, according to the manufacturer’s instructions
(Figure 1). In Peru, the assay was performed from a third sputum
sample if provided and from the ﬁrst sputum sample if not. This
third sample underwent only direct ZN and FM smears before
concentration with NALCNaOH then Xpert MTB/RIF testing. In
Brazil and Vietnam, after NALCNaOH concentration, >0.5 ml of
the remainder of the ﬁrst sample collected was frozen at 70 C
and tested by Xpert MTB/RIF after 2–6 months.
Any sample reported as positive for MTB by the automated
output from the Xpert MTB/RIF was considered positive, while
samples reported as MTB-negative were considered negative. Any
error, invalid, or no result value was considered indeterminate and
ineligible for sensitivity/speciﬁcity analysis. 95% CI were obtained
using the binomial distribution. Blinding was deemed unnecessary
given the automated nature of the test.
Results
Between January and December 2012, 1036 eligible participants
were enrolled across the four sites (Table 1). Results from 25
participants were excluded from analysis for the following
reasons: two for having more than two contaminated cultures;
ﬁve were culture-positive but missing results of MPT64; 13 had a
single positive culture after >28 days or <20 colonies; two were
missing smear results; three were found to be culture-positive and
NTM but only at follow-up.
Across all sites, there were 375 culture-positive TB cases, 477
non-TB participants, 43 with clinically diagnosed TB, and 69 with
possible TB. These were the 964 participants and 1928 sputum
samples in the primary analysis (Figure 2). There were 38
participants with NTM (29/38) or mixed MTB–NTM infections
(9/38) who were analyzed separately (Table 2). Also analyzed
separately were nine FM smear-positive, culture-negative individ-
uals.
The follow-up rate among individuals with a positive TB-LAMP
and all negative smear/culture results was 75% (15/20), while the
follow-up rate among participants with negative results on all tests
was 67% (381/572) (Table 1). The overall follow-up rate for those
with negative smear/culture results in South Africa was 93% (169/
182) and in Peru was 99% (153/154), while in Vietnam it was only
62% (63/102). In Brazil, 79% (11/14) of participants with a positive
TB-LAMP and negative smear/culture were followed up, but none
of those who were negative on all tests were followed up due to
programmatic restrictions.
The overall TB-LAMP indeterminate rate was 0.3%. Two out of
2081 TB-LAMP tests performed could not be interpreted after two
readings and four had a positive result from the negative control,
indicating likely DNA contamination for that run of the assay. All
had clear positive or negative results after repetition of the TB-
LAMP assay on the same sputum.
For the 375 participants with culture-positive TB and with two
sputum samples each (750 samples), 567 of these samples tested
positive by TB-LAMP, giving a sensitivity of 75.6% (567/750; 95% CI
71.8–79.4%). Sensitivity was 97.9% (415/424; 95% CI 96.4–99.4%)
and 46.6% (152/326; 95% CI 40.6–52.7%) in direct ZN smear-
positive and smear-negative TB samples, respectively (Table 3).
Overall results classiﬁed using direct FM smears were similar
(direct FM results include only Peru, Vietnam, and Brazil).
Nine hundred and forty-two of 954 sputum samples from 477
non-TB participants tested negative on TB-LAMP, giving an overall
speciﬁcity of 98.7% (95% CI 97.9–99.6%) (Table 3). Inclusion of
follow-up information made the greatest impact in Brazil where
speciﬁcity was 97.2% (282/290; 95% CI 95.2–99.3%) but only 94.7%
(286/302; 95% CI 91.8–97.6%) exclusive of follow-up (i.e., inclusive
only of initial clinical and laboratory ﬁndings and whether the
individual was immediately put on treatment). In Vietnam,
speciﬁcity also improved with the inclusion of follow-up (98.3%;
118/120; 95% CI 95.0–100%). Speciﬁcity in Peru was 99.6% (279/
280; 95% CI 98.9–100%) and in South Africa was also 99.6% (263/
264; 95% CI 98.9–100%); at these sites, speciﬁcity was similar
irrespective of whether follow-up data were considered or not.
Only South Africa had a signiﬁcant number of HIV-positive
individuals (35.5%). The overall sensitivity of TB-LAMP in sputum
samples from culture-positive, HIV-positive participants was 51.9%
(28/54; 95% CI 34.1–69.6%). By smear status, in HIV-positive
participants, sensitivity was 100% (19/19; 95% CI 82.4–100%) in
smear-positive samples and 26.3% (9/35; 95% CI 8.6–42.9%) in
smear-negative samples.
The performance of TB-LAMP was compared to that of Xpert
MTB/RIF (Table 4). In this study, overall sensitivity in smear-
Table 1
Demographic characteristics.
Peru South Africa Brazil Vietnam Overall
Included/enrolled 196/199 245/259 224/266 299/312 964/1036
Male, n (%) 98 (50%) 161 (66%) 138 (62%) 210 (70%) 607 (63%)
Age, years, median (range) 41 (18–86) 38 (18–77) 48 (18–81) 37 (18–81) 40 (18–86)
HIV-positive, n (%) 2 (1.0%) 87 (36%) 1 (0.4%) 6 (2.0%) 96 (10%)
Culture-positive TB prevalence, n (%) 42 (21%) 63 (26%) 72 (32%) 198 (66%) 375 (39%)
Smear-negative, culture-positive TB prevalencea, n (%) 22 (11%) 32 (13%) 14 (6%) 88 (29%) 156 (16%)
Clinical TB prevalence, n (%) 4 (2.0%) 14 (5.7%) 3 (1.3%) 22 (7.4%) 43 (4.5%)
NTM only, n (%) 1 (0.5%) 0 (0.0%) 22 (8.3%) 6 (1.9%) 29 (2.8%)
Follow-up rate among TB-LAMP-positive, culture-negative (%) 1/1 (100%) 0/1 (0%) 11/14 (79%) 3/4 (75%) 15/20 (75%)
Follow-up rate among TB-LAMP-negative, culture-negative (%) 152/153 (99%) 169/181 (93%) 0/140 (0%) 60/98 (61%) 381/572 (67%)
NTM, non-tuberculous mycobacteria; TB, tuberculosis.
a Based on two direct Ziehl–Neelsen smears.
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Figure 2. Participants and sputum samples—diagnostic breakdown (Abbreviations: S+C+, smear-positive, culture-positive; SC+, smear-negative, culture-positive; CI,
conﬁdence interval; TB, tuberculosis).
Table 2
TB-LAMP samples analyzed separately among those with NTM or mixed MTB–NTM infections.
Peru South Africa Brazil Vietnam Overall
Clinical TB (+/n) 0/8 0/28 1/6 1/44 2/86
Possible TB (+/n) 0/20 0/72 5/8 3/38 8/138
ZN smear-positive, culture negative (+/n) 0/0 0/0 0/0 0/0 0/0
FM smear-positive, culture-negative (+/n) 0/1 0/0 0/7 0/1 0/9
NTM sample only (/n) 1/1 0/0 25/35 6/15 32/51
Mixed infection, MTB sample only (+/n) 0/0 0/0 2/5 4/4 6/9
+/n, number of positive samples out of the total number of samples; /n, number of negative samples out of the total number of samples; FM, ﬂuorescence microscopy; MTB,
Mycobacterium tuberculosis; NTM, non-tuberculous mycobacteria; TB, tuberculosis; ZN, Ziehl–Neelsen.
Table 3
TB-LAMP performance in a single direct sputum sample per participant (using two samples per participant).
Peru South Africaa Brazil Vietnam Overall
Sensitivity
Culture-positive TB 89.3% 68.3% 86.8% 71.0% 75.6%
95% CI 80.0–98.5 57.6–78.9 80.1–93.5 65.6–76.3 71.8–79.4
(m/n) (75/84) (86/126) (125/144) (281/396) (567/750)
Direct ZN smears Smear-positive TB 100% 98.2% 100% 96.2% 97.9%
95% CI 92.1–100 94.8–100 96.7–100 93.4–99.1 96.4–99.4
(m/n) (45/45) (56/57) (109/109) (205/213) (415/424)
Smear-negative TB 76.9% 43.5% 45.7% 41.5% 46.6%
95% CI 58.6–95.2 29.2–57.7 28.9–62.5 34.0–49.1 40.6–52.7
(m/n) (30/39) (30/69) (16/35) (76/183) (152/326)
Direct FM smears Smear-positive TB 98.4% – 100% 92.4% 95.0%
95% CI 95.2–100 95.6–100 88.6–96.2 92.5–97.5
(m/n) (61/62) (82/82) (218/236) (361/380)
Smear-negative TB 63.6% – 69.4% 39.4% 49.2%
95% CI 33.3–94.0 56.182.6 31.2–47.5 42.0–56.4
(m/n) (14/22) (43/62) (63/160) (120/244)
Speciﬁcity
Non-TB, including follow-up 99.6% 99.6% 97.2% 98.3% 98.7%
95% CI 98.9–100 98.9–100 95.2–99.3 95.0–100 97.9–99.6
(m/n) (279/280) (263/264) (282/290) (118/120) (942/954)
Non-TB, excluding follow-up 99.7% 99.7% 94.7% 96.9% 97.9%
95% CI 99.0–100 99.1–100 91.8–97.6 93.2–100 96.9–98.9
(m/n) (299/300) (335/336) (286/302) (155/160) 1075/1098
CI, conﬁdence interval; m, TB-LAMP-positive or negative samples; n, total number of samples; TB, tuberculosis; ZN, Ziehl–Neelsen microscopy; FM, ﬂuorescence microscopy.
a South Africa performed only direct Ziehl–Neelsen smears.
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positive TB cases was 97.9% (415/424; 95% CI 96.4–99.4%) for TB-
LAMP and 99.0% (207/209; 95% CI 96.6–99.9%) for Xpert MTB/RIF
(p = 0.32, Pearson’s x2 test). Sensitivity in smear-negative TB cases
was 46.6% (152/326; 95% CI 40.6–52.7%) for TB-LAMP and 52.3%
(81/158; 95% CI 43.2–59.3) for Xpert MTB/RIF (p = 0.63). Speciﬁcity
was 98.7% (942/954; 95% CI 97.9–99.6%) for TB-LAMP and 97.2%
(457/470; 95% CI 95.3–98.5%) for Xpert MTB/RIF (p = 0.07). The
Xpert MTB/RIF indeterminate rate was 0.9% (9/973).
Discussion
This study was successful in demonstrating the performance of
the TB-LAMP assay. TB-LAMP can reliably detect nearly all smear-
positive TB cases and roughly half of smear-negative TB cases from
a single raw sputum sample. In this study in TB reference
laboratories, no signiﬁcant difference in sensitivity and speciﬁcity
was found for TB-LAMP compared to Xpert MTB/RIF using four
direct smears and four cultures as the reference standard.
Brazil had the lowest speciﬁcity rates for TB-LAMP and Xpert
MTB/RIF, as well as the least follow-up information. Given
programmatic capabilities, follow-up was only asked of partic-
ipants positive on TB-LAMP and with bacteriologically negative
results (79% follow-up rate); this resulted in signiﬁcant improve-
ment in the TB-LAMP speciﬁcity (94.7% excluding follow-up and
97.2% including follow-up). Directed follow-up was not performed
for participants with Xpert MTB/RIF-positive and bacteriologically
negative results; furthermore, the use of an imperfect standard
will have a more deleterious effect on an assay with higher
speciﬁcity. Although it could not be conﬁrmed, it is possible that
specimen decontamination before culture in Brazil was performed
using 2% NaOH (where 1–1.5% is recommended), which would
have destroyed weakly growing mycobacteria, thereby lowering
culture sensitivity (Kent and Kubica, 1985; Global Laboratory
Initiative, 2014). This hypothesis is further supported by the high
number of smear-positive, culture-negative results found in Brazil.
Finally, the laboratory in Brazil had lower sensitivity using FM
(45.7%) than the more standard ZN (69.4%) – the opposite of what
would be expected based on a previous meta-analysis of the two
methods (Steingart et al., 2006).
Excluding Brazil, speciﬁcity would be 99.4% for TB-LAMP across
the other three countries and 99.7% for Xpert MTB/RIF. This
speciﬁcity for Xpert MTB/RIF agrees with data reported in the
literature (Steingart et al., 2014).
Peru had an unusually high TB-LAMP sensitivity in ZN smear-
negatives (76.9%), while Vietnam had unusually low TB-LAMP
sensitivity in FM smear-negatives (39.4%). These variations may
reﬂect the variability of smear performance from one laboratory to
another. The same variability from site to site is seen for Xpert
MTB-RIF as well, supporting this conclusion.
In conclusion, while this study was limited in that complete
follow-up and standardization of the protocol was not possible, the
ﬁndings contribute to the growing literature on the performance of
molecular assays in the intended populations. Given the ﬁnding in
this study that laboratory performance of TB-LAMP approaches
that of Xpert MTB/RIF, further studies are recommended in settings
of intended use to evaluate these expected beneﬁts.
The use of a manual technique may give TB-LAMP the potential
to enter the market at a lower cost than its automated counterpart
(Vassall et al., 2011). It is hoped that the limited infrastructure
needed to reliably power a heating block for 40 min will make it
possible to run this assay in decentralized settings. Furthermore,
the higher throughput of this assay, with up to 14 tests per batched
2-h run, may accommodate laboratories with moderate to high
workloads at any level of the health system.
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